2 terminated, 1 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 2, Completed 1 |
Follow Qge031: new trials by email Literature Review of Qge031 trials Research Report on Qge031
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines Ligelizumab, Placebo - Chronic Inducible Urticaria | Phase 3 | Terminated | Novartis Pharmaceuticals | 39 | 2021-11-16 | 2024-06-18 |
| Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab Ligelizumab - Chronic Spontaneous Urticaria | Phase 3 | Terminated | Novartis Pharmaceuticals | 1033 | 2020-04-08 | 2024-06-20 |
| A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines Ligelizumab - Chronic Spontaneous Urticaria | Phase 3 | Completed | Novartis Pharmaceuticals | 66 | 2019-04-13 | 2025-03-06 |
Chronic Urticaria (2) · Chronic Inducible Urticaria (1) · Cold Urticaria (1) · Familial dermographism (1) · Pruritus (1) · Urticaria (1)
Australia (2) · Greece (2) · Hungary (2) · Japan (2) · Russia (2) · Slovakia (2) · Spain (2) · Taiwan (2) · Turkey (Türkiye) (2) · United States (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1)
2019 (1)